Risk is the price of admission for innovation. Every new product, scientific breakthrough, or business model starts as an uncertain bet, and the willingness to place that bet largely determines whether innovation happens at all. The relationship works in both directions: taking smart risks drives breakthroughs, while avoiding risk leads to stagnation. Understanding how this dynamic plays out helps explain why some companies and institutions consistently innovate while others fall behind.
Why Innovation Requires Risk by Definition
Innovation means doing something that hasn’t been done before, and anything untested carries uncertainty about whether it will work, whether people will want it, and whether it will generate a return. Funding an innovative project means committing real money with no guarantee of future profitability. That’s risk in its most basic form.
Prospect theory, the Nobel Prize-winning framework developed by Daniel Kahneman and Amos Tversky, helps explain why this matters. People and organizations don’t evaluate risky decisions rationally. They tend toward risk aversion when things are going well (protecting what they have) and risk-seeking behavior when they’re losing ground (gambling on a comeback). This means a company’s appetite for innovation often depends less on the quality of the idea and more on how secure or threatened it feels. A dominant market leader may avoid a promising new technology simply because the potential downside feels larger than the upside, even when the math says otherwise.
The Numbers Behind Innovation Risk
The failure rates in innovation-heavy industries make the stakes concrete. In pharmaceutical development, an analysis of over 2,000 compounds and nearly 20,000 clinical trials conducted by 18 leading companies between 2006 and 2022 found that the average likelihood of a drug making it from Phase I trials to FDA approval was just 14.3%. Some companies managed approval rates around 23%, while others succeeded only 8% of the time. The broader industry benchmark has historically hovered around 10%. That means pharmaceutical companies pour billions into research knowing that roughly 6 out of every 7 compounds they develop will never reach patients.
Startups face similarly brutal odds. Roughly 9 out of 10 startups fail. Even with venture capital backing, 75% never return a single dollar to their investors. The timeline is telling: about 10% fail in their first year, and another 70% collapse between years two and five. Among tech startups specifically, 63% fail within five years. The most common causes are poor product-market fit (34%), failed marketing (29%), and team dysfunction (23%). One research group found that 70% of startup failures happen because founders scale too early, essentially taking the wrong risks at the wrong time.
These numbers aren’t arguments against risk. They’re illustrations of what risk actually looks like when you’re trying to create something new. The companies and founders who succeed aren’t avoiding risk; they’re navigating it more skillfully.
What Happens When Organizations Avoid Risk
The consequences of excessive risk aversion are well documented and often more damaging than the risks themselves. The pattern described in Clayton Christensen’s famous “innovator’s dilemma” captures this perfectly: established companies miss major market transitions because they’re too focused on serving their existing customers with familiar technology.
The hard disk drive industry offers a clean example. Seagate, once dominant in 5.25-inch drives, was reluctant to invest in smaller 3.5-inch technology because it would cannibalize their existing business. As one industry executive put it, the new technology “encroached on their 5.25-inch business,” making the risk feel unacceptable. Economic modeling of this dynamic found that cannibalization was the single most important factor holding incumbents back. Without the fear of cannibalizing existing products, the innovation gap between established companies and new entrants would have shrunk by 57%.
This is what economists call the “replacement effect”: a company already profiting from an existing technology has less incentive to introduce something new than a challenger with nothing to lose. The monopolist only captures the gains above what it already earns, while the newcomer captures everything. The result is that market leaders often let smaller, hungrier competitors define the next generation of technology. The risk of innovating feels too high, right up until the risk of not innovating destroys the business entirely.
How Organizations Balance Risk and Innovation
Smart organizations don’t eliminate risk from innovation. They manage it through portfolio thinking. The basic principle is straightforward: mix high-risk, high-reward projects with safer, incremental improvements. This way, the cautious bets keep generating revenue while the ambitious ones have room to either fail cheaply or succeed spectacularly. Product managers often use structured frameworks to map their portfolio across categories, ensuring resources aren’t concentrated entirely on safe projects or entirely on moonshots.
At the national level, global R&D spending reflects how seriously countries take this bet. Total worldwide R&D expenditures reached $3.1 trillion in 2022. The United States led with $923 billion (30% of the global total), followed by China at $812 billion (27%). Countries that invest the most intensely relative to their economy include Israel, which spends 6.0% of GDP on R&D, and South Korea at 5.2%. The United States sits at 3.6%. These investments are, by definition, bets on uncertain outcomes, and the countries making the biggest bets tend to produce the most innovation.
Funding High-Risk Ideas Deliberately
Some institutions have built programs specifically designed to fund risky ideas that would otherwise never get support. The NIH’s High-Risk, High-Reward Research program is one of the clearest examples. It was created to accelerate biomedical and behavioral science discoveries by backing “exceptionally creative scientists conducting highly innovative research.” The program targets ideas that are too early-stage or too unconventional to survive traditional peer review, where reviewers tend to favor safe, well-supported proposals.
One component, the NIH Director’s Transformative Research Award, specifically funds proposals that “could create or challenge existing paradigms.” Applicants don’t even need preliminary data, a requirement that would normally be non-negotiable in government-funded science. The program exists because the standard funding process systematically filters out exactly the kind of work most likely to produce breakthroughs. By removing the usual barriers, it creates a protected space for the riskiest and potentially most valuable research.
The Human Side: Psychological Safety
Risk in innovation isn’t only financial. There’s also the social risk of proposing an idea that might fail, challenging a superior, or admitting you don’t know something. Research consistently shows that reducing this kind of interpersonal risk boosts innovation. A study published in PLoS One examined how psychological safety within teams affects individual innovative performance and found significant positive effects across three dimensions: team collaboration and understanding, information sharing, and balanced give-and-take among members. All three predicted higher innovation output at high levels of statistical significance.
This makes intuitive sense. If suggesting an unconventional idea might get you ridiculed or punished, you’ll keep it to yourself. Multiply that across an entire organization and you get a culture where only safe, predictable ideas survive. The companies that innovate most effectively tend to be the ones where people feel safe proposing something that might not work, because that’s where every breakthrough starts.
Risk as a Competitive Advantage
The relationship between risk and innovation ultimately comes down to selection pressure. In any market or field, the players willing to take calculated risks gain access to opportunities that risk-averse competitors never even see. A pharmaceutical company that runs more clinical trials, knowing most will fail, still ends up with more approved drugs than one that only pursues sure things. A startup ecosystem where failure is expected and tolerated produces more successful companies than one where a single failure ends a career.
The key distinction is between reckless risk and managed risk. Reckless risk ignores the odds, pours resources into a single bet, and scales before validating the core idea. Managed risk acknowledges the odds, spreads bets across a portfolio, tests assumptions early, and creates environments where people can fail without catastrophic consequences. Innovation depends on risk not because failure is desirable, but because the willingness to fail is inseparable from the willingness to try something genuinely new.